BRIEF—Janssen Immunology names David Jimenez as new president

David Jimenez is stepping in as the new president of Janssen Immunology to lead the business in its mission of relentlessly advancing care for people living with immune-mediated diseases.

This role is the latest chapter in Mr Jimenez’s more than 20-year journey with Janssen parent company Johnson & Johnson.

Prior to this appointment, he served as president of Janssen’s Pulmonary Hypertension business.

He brings to Immunology a strong track record of success through his diverse, global, cross-sector experiences and a “one team, all-in approach” that will ensure Janssen continues to deliver on its legacy of excellence.

Commenting on the move, Mr Jimenez said: “I am deeply grateful for my time leading Janssen’s Pulmonary Hypertension organization the past two years – thanks to a resilient and dedicated team, and passionate community who, together, helped us make significant health advances for PH patients. The rare disease community has taught me so much, and I will apply the same approach of listening and learning to make the greatest impact for patients as I start this new chapter.”